DAVE LEMUS APPOINTED CHIEF OPERATING OFFICER OF SIGMA-TAU PHARMACEUTICALS, INC.
GAITHERSBURG, MD – March 09, 2012 - Sigma-Tau Pharmaceuticals, Inc.’s Board of Directors today announced the appointment of Dave Lemus as Chief Operating Officer of Sigma Tau Pharmaceuticals, Inc., following the resignation of his predecessor, Gregg Lapointe, whose duties Mr. Lemus will now assume with immediate effect. Additionally, the Board of Directors announced the approval of a new organizational structure within Sigma-Tau Pharmaceuticals, Inc., which affirms the Company’s strategy and commitment to rare disease patients.
Commenting on behalf of the Board of Directors, Professor Trevor Jones CBE, President of Sigma-Tau Pharmaceuticals, said: “We are delighted to appoint Dave to lead our efforts to expand the world-class rare disease business we have established in the U.S. Dave brings a wealth of relevant pharmaceutical and biotech experience from both the U.S. and Europe. His appointment will serve to further strengthen our unwavering mission to serve the needs of orphan drug and rare disease patients.”
Prior to his tenure at Sigma-Tau, Mr. Lemus served as Chief Financial Officer of MorphoSys AG, where he launched Germany’s first-ever biotech IPO in 1999. Before this, Mr. Lemus worked in variety of senior management roles at Hoffmann-La Roche and Lindt in Switzerland. Mr. Lemus presently serves as Board Chairman of Proteros GmbH in Munich, Germany, and a Non-Executive Board member of Axela, in Toronto, Canada.
About Sigma-Tau Pharmaceuticals, Inc.:
Sigma-Tau Pharmaceuticals, Inc. is a U.S. based, wholly owned subsidiary of the sigma-tau Group, and is dedicated solely to the global development and commercialization of medicines for patients with rare diseases. Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Maryland. Since 1989, the company’s products have been focused on rare diseases, including kidney disease, certain genetic disorders and cancers. With more than 7,000 identified rare diseases that affect approximately 30 million patients in the Unites States, Sigma-Tau places its considerable scientific resources behind the development and commercialization of compounds that benefit the few. The company has a substantial development program focused on transplant, cancer, inherited genetic disorders, malaria, and other areas of unmet medical need. For more information about the company, visit www.sigmatau.com.